BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
- Conditions
- Psoriasis Vulgaris
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00306878
- Locations
- ๐บ๐ธ
Local Institution, Pittsburgh, Pennsylvania, United States
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 63
- Registration Number
- NCT00306202
- Locations
- ๐ฌ๐ง
Local Institution, Birmingham, West Midlands, United Kingdom
Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies
- Conditions
- Gastrointestinal Neoplasms
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT00300027
- Locations
- ๐บ๐ธ
Local Institution, Temple, Texas, United States
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
- Conditions
- Leukemia, Myeloid, ChronicLeukemia, Lymphocytic, Acute, L2
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT00298987
- Locations
- ๐จ๐ฆ
Local Institution, Montreal, Quebec, Canada
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
- Conditions
- Lymphoma, Large-Cell
- First Posted Date
- 2006-03-02
- Last Posted Date
- 2010-04-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00298467
- Locations
- ๐บ๐ธ
California Oncology of the Central Valley, Fresno, California, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
๐บ๐ธCity of Hope, National Medical Center, Duarte, California, United States
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: MDX-1100 (anti-CXCL10 human monoclonal antibody)
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT00295282
- Locations
- ๐บ๐ธ
University of Medicine and Dentistry of New Jersery (UMDNJ), New Brunswick, New Jersey, United States
๐บ๐ธCedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธMount Sinai School of Medicine, New York, New York, United States
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 210
- Registration Number
- NCT00289640
- Locations
- ๐บ๐ธ
Center For Oncology Research & Treatment, P.A., Dallas, Texas, United States
๐บ๐ธOncology Specialists, Sc, Park Ridge, Illinois, United States
๐บ๐ธSt Joseph Oncology Inc, St Joseph, Missouri, United States
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 155
- Registration Number
- NCT00289627
- Locations
- ๐บ๐ฆ
Local Institution, Uzhgorod, Ukraine
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
- Conditions
- Psoriasis Vulgaris
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 144
- Registration Number
- NCT00287547
- Locations
- ๐บ๐ธ
Local Institution, Burlington, Vermont, United States
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT00284804
- Locations
- ๐บ๐ธ
Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
๐บ๐ธCalifornia Oncology of the Central Valley, Fresno, California, United States
๐บ๐ธAmerican Health Network of Indiana, Indianapolis, Indiana, United States